obesity

News

Lilly ends ADA on a high as obesity triple data pops

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Weight-loss drugs ‘will be a $60bn market in 10 years’

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,

News

UK plans $40m pilot of obesity drug Wegovy in primary care

Novo Nordisk’s obesity drug isn’t even available in the UK yet, but the government has already launched a pilot programme that could see access to the drug expanded throug

News

Novo Nordisk says oral Wegovy hits weight loss goal

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W

News

Boehringer shows its hand in obesity

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge

Lilly ends ADA on a high as obesity triple data pops

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

Weight-loss drugs ‘will be a $60bn market in 10 years’

UK plans $40m pilot of obesity drug Wegovy in primary care

Novo Nordisk says oral Wegovy hits weight loss goal

Boehringer shows its hand in obesity

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

obesity

Editor's Picks